CARDISURE FLAVOURED 10 MG TABLETS FOR DOGS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

PIMOBENDAN

Available from:

Eurovet Animal Health B.V.

ATC code:

QC01CE90

INN (International Name):

PIMOBENDAN

Dosage:

10 Milligram

Pharmaceutical form:

Tablets

Prescription type:

POM

Therapeutic group:

Canine

Therapeutic area:

Pimobendane

Therapeutic indications:

Cardiovascular

Authorization status:

Authorised

Authorization date:

2011-07-22

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Cardisure flavoured 10 mg Tablets For dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
10 mg
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
Light brown, round tablets, scored on one side and plain on the other side.
The tablets can be divided into 4 equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid
regurgitation) or dilated cardiomyopathy.
4.3 CONTRAINDICATIONS
Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is
not possible for functional or anatomical reasons (e.g. aortic stenosis).
See also section 4.7.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The product should be administered on an empty stomach at least one hour before meals, as absorption is reduced when
given with feed.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 08/07/2016_
_CRN 7022256_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
The product is flavoured. To avoid accidental ingestion the tablets should be stored out of reach of dogs.
An _in vitro _study in rat tissue demonstrated that pimobendan increased glucose-induced insulin release from pancreatic -
cells in a dose-dependent manner. If the product is administered to diabetic dogs, blood glucose levels should be carefully
monitored.
As pimobendan is metabolised in the liver, particular care should be taken
                                
                                Read the complete document
                                
                            

Search alerts related to this product